Coronary artery disease (CAD) is the leading cause of death and disability world over. To achieve PCI; either bare metal stent (BMS) or drug eluting stent (DES) are used. The objective of the present retrospective study was to evaluate pharmacoeconomics between BMS (Driver TM) and DES (Endeavor TM) in patients who underwent coronary angioplasty. 20 patients underwent PCI between December 2007 and June 2009 at The Heart Care Clinic, Ahmedabad, out of which 10 patients were implanted with Zotarolimus Eluting Stent (ZES) and 10 were implanted with BMS. Both groups had similar demographics and risks factors. Follow-up was conducted. In pharmacoeconomics cost and effectiveness in terms of quality of life (Seattle Angina Questionnaires) and quality adjusted life years (QALY) was analyzed. Cost (in Indian Rupees) of BMS and DES was 96225±34732 and 152967±39086 (p<0.0001*), respectively. Effectiveness in term of QALY (Quality adjusted Life Year gained) was 1.58±0.33 in BMS group patients and 2.05±0.38 in DES group patients (p<0.0001*). The Pharmacoeconomical prospective show DES was a better compared to BMS which was statistically significant.